Celltrion USA seeks FDA approval for CT-P47 biosimilar

29 Jan 2024
www.pharmaceutical-technology.com
Drug ApprovalPhase 3Immunotherapy
Celltrion USA seeks FDA approval for CT-P47 biosimilar
Preview
Source: Pharmaceutical Technology
Celltrion USA’s FDA BLA submission is for CT-P47 to treat rheumatoid arthritis. Credit: Oporty786 / Shutterstock.com.
Celltrion USA, the American subsidiary of the biopharmaceutical company Celltrion, has filed a biologics licence application (BLA) with the US Food and Drug Administration (FDA) for its biosimilar candidate CT-P47.
CT-P47 is a biosimilar candidate of the reference product ACTEMRA (tocilizumab).
The application sought approval for the drug to treat moderate to severe active rheumatoid arthritis.
The BLA for CT-P47 is supported by data from an international Phase III clinical trial.
The trial assessed the pharmacokinetics, safety, efficacy and immunogenicity of CT-P47 versus ACTEMRA in patients with rheumatoid arthritis who had an inadequate response to methotrexate.
ACTEMRA is currently approved for indications including adult rheumatoid arthritis and juvenile idiopathic arthritis conditions.
Celltrion is seeking approval for intravenous and subcutaneous administration routes for CT-P47.
Founded in 2018, Celltrion USA aims to increase the availability of innovative biologics in the US healthcare market.
The company plans to use Celltrion’s expertise in biotechnology, supply chain management and sales to enhance the accessibility of high-quality biopharmaceuticals for patients in the US.
Celltrion has a presence in 110 countries, offering cost-effective biopharmaceutical solutions.
The FDA approved Celltrion USA’s Zymfentra as maintenance therapy in adults with ulcerative colitis and Crohn’s disease in October 2023.
Zymfentra, a subcutaneous version of Celltrion USA’s Remsima, is a biosimilar to Janssen’s Remicade (infliximab).
Remsima gained approval in Europe in September 2013 as the world’s first monoclonal antibody biosimilar and was approved by the FDA in April 2016 under the name Inflectra.
Celltrion USA chief commercial officer Thomas Nusbickel stated: “The submission of CT-P47 for review is an important step toward providing patients with rheumatoid arthritis a more accessible avenue to treatment for conditions that present such a significant disease burden.
“We plan to lead the market by establishing a diverse product line-up in the autoimmune disease market in the US.
“We will continue to actively co-operate with the FDA’s review in an effort to bring this new treatment option to people living with rheumatoid arthritis as soon as possible.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.